Tags

Type your tag names separated by a space and hit enter

The risk of cervical atypia in oral contraceptive users.

Abstract

BACKGROUND

The interactions of oral contraceptive (OC) use, risk of human papillomavirus (HPV) infection and associated cellular atypia are complex. We investigated the association between history of OC-use, and cytological or histopathological abnormalities in a cohort of non-HPV vaccinated originally 16-17-year-old women participating the PATRICIA trial for 4 years.

METHODS

The total number of hepatitis A-virus (control) vaccine recipients participating in the clinical PATRICIA trial in Finland was 2399. Nine-hundred and ninety-nine women returned questionnaires on living conditions-life habits and sexual health after completing the study. Mean age at answering the questionnaire at the end of the clinical trial was 22 years. Age at sexual debut varied between 12 and 16 years for majority of the women. Cervical cytological samples were obtained every 6 months throughout the PATRICIA trial. The relative risk of cervical atypia associated with time since start of oral contraceptives use was calculated as odds ratio (OR) with 95% confidence interval (CI) using logistic regression.

RESULTS

Compared to never-users, the smoking and age-at-sexual-debut adjusted relative risk of cervical intraepithelial neoplasia grade 1 (CIN1) in women who had started the use of oral contraceptives for more than 1 year was low (OR 0.2, 95% CI: 0.1-0.7). Risk of cytological atypia was also reduced (OR 0.6) albeit not significantly (95% CI: 0.3-1.3).

CONCLUSIONS

Use of oral contraceptives does not increase the risk of cervical atypia but when established might instead be protective.

Authors+Show Affiliations

a Department of Health Sciences , University of Tampere , Tampere , Finland.a Department of Health Sciences , University of Tampere , Tampere , Finland.b Karolinska Institute , Huddinge , Sweden.b Karolinska Institute , Huddinge , Sweden.c VL-Medi , Helsinki , Finland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29412045

Citation

Adhikari, Indira, et al. "The Risk of Cervical Atypia in Oral Contraceptive Users." The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, vol. 23, no. 1, 2018, pp. 12-17.
Adhikari I, Eriksson T, Luostarinen T, et al. The risk of cervical atypia in oral contraceptive users. Eur J Contracept Reprod Health Care. 2018;23(1):12-17.
Adhikari, I., Eriksson, T., Luostarinen, T., Lehtinen, M., & Apter, D. (2018). The risk of cervical atypia in oral contraceptive users. The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, 23(1), pp. 12-17. doi:10.1080/13625187.2018.1431214.
Adhikari I, et al. The Risk of Cervical Atypia in Oral Contraceptive Users. Eur J Contracept Reprod Health Care. 2018;23(1):12-17. PubMed PMID: 29412045.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The risk of cervical atypia in oral contraceptive users. AU - Adhikari,Indira, AU - Eriksson,Tiina, AU - Luostarinen,Tapio, AU - Lehtinen,Matti, AU - Apter,Dan, Y1 - 2018/02/07/ PY - 2018/2/8/pubmed PY - 2018/10/16/medline PY - 2018/2/8/entrez KW - ASCUS KW - HPV KW - cervical neoplasia KW - contraceptives KW - squamous intraepithelial lesion SP - 12 EP - 17 JF - The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception JO - Eur J Contracept Reprod Health Care VL - 23 IS - 1 N2 - BACKGROUND: The interactions of oral contraceptive (OC) use, risk of human papillomavirus (HPV) infection and associated cellular atypia are complex. We investigated the association between history of OC-use, and cytological or histopathological abnormalities in a cohort of non-HPV vaccinated originally 16-17-year-old women participating the PATRICIA trial for 4 years. METHODS: The total number of hepatitis A-virus (control) vaccine recipients participating in the clinical PATRICIA trial in Finland was 2399. Nine-hundred and ninety-nine women returned questionnaires on living conditions-life habits and sexual health after completing the study. Mean age at answering the questionnaire at the end of the clinical trial was 22 years. Age at sexual debut varied between 12 and 16 years for majority of the women. Cervical cytological samples were obtained every 6 months throughout the PATRICIA trial. The relative risk of cervical atypia associated with time since start of oral contraceptives use was calculated as odds ratio (OR) with 95% confidence interval (CI) using logistic regression. RESULTS: Compared to never-users, the smoking and age-at-sexual-debut adjusted relative risk of cervical intraepithelial neoplasia grade 1 (CIN1) in women who had started the use of oral contraceptives for more than 1 year was low (OR 0.2, 95% CI: 0.1-0.7). Risk of cytological atypia was also reduced (OR 0.6) albeit not significantly (95% CI: 0.3-1.3). CONCLUSIONS: Use of oral contraceptives does not increase the risk of cervical atypia but when established might instead be protective. SN - 1473-0782 UR - https://www.unboundmedicine.com/medline/citation/29412045/The_risk_of_cervical_atypia_in_oral_contraceptive_users_ L2 - http://www.tandfonline.com/doi/full/10.1080/13625187.2018.1431214 DB - PRIME DP - Unbound Medicine ER -